This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Idogen Crescita futura

Future criteri di controllo 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Idogen.

Informazioni chiave

50.6%

Tasso di crescita degli utili

76.1%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	46.4%
Tasso di crescita dei ricavi	-122.1%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	10 May 2023

Aggiornamenti recenti sulla crescita futura

Nessun aggiornamento

Recent updates

Previsioni di crescita degli utili e dei ricavi

OM:IDOGEN - Stime future degli analisti e dati finanziari passati (SEK Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2025	N/A	-12	-12	-12	2
12/31/2024	N/A	-12	-11	-12	2
12/31/2023	N/A	-37	-39	-38	2
3/31/2023	1	-44	-42	-40	N/A
12/31/2022	0	-48	-52	-51	N/A
9/30/2022	3	-50	-55	-53	N/A
6/30/2022	11	-41	-54	-52	N/A
3/31/2022	12	-39	-48	-48	N/A
12/31/2021	14	-39	-41	-40	N/A
9/30/2021	13	-33	-36	-36	N/A
6/30/2021	7	-33	-34	-33	N/A
3/31/2021	8	-31	-37	-36	N/A
12/31/2020	8	-27	-28	-28	N/A
9/30/2020	7	-27	-25	-25	N/A
6/30/2020	6	-29	-27	-27	N/A
3/31/2020	5	-32	-25	-25	N/A
12/31/2019	4	-33	-36	-35	N/A
9/30/2019	7	-29	-29	-28	N/A
6/30/2019	6	-30	-28	-26	N/A
3/31/2019	5	-27	-30	-27	N/A
12/31/2018	4	-28	-14	-10	N/A
9/30/2018	N/A	-30	-24	-18	N/A
6/30/2018	N/A	-29	-24	-19	N/A
3/31/2018	N/A	-25	-18	-12	N/A
12/31/2017	N/A	-21	-24	-20	N/A
9/30/2017	0	-18	-17	-15	N/A
6/30/2017	0	-14	-11	-9	N/A
3/31/2017	0	-13	-12	-12	N/A
12/31/2016	0	-13	N/A	-11	N/A
9/30/2016	0	-12	N/A	-12	N/A
6/30/2016	0	-12	N/A	-12	N/A
3/31/2016	0	-10	N/A	-10	N/A
12/31/2015	0	-10	N/A	-9	N/A
9/30/2015	0	-8	N/A	-8	N/A
6/30/2015	1	-6	N/A	-5	N/A
3/31/2015	0	-4	N/A	-3	N/A
12/31/2014	0	-2	N/A	-2	N/A
12/31/2013	0	0	N/A	0	N/A
12/31/2012	0	0	N/A	N/A	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: IDOGEN is forecast to remain unprofitable over the next 3 years.

Guadagni vs Mercato: IDOGEN is forecast to remain unprofitable over the next 3 years.

Guadagni ad alta crescita: IDOGEN is forecast to remain unprofitable over the next 3 years.

Ricavi vs Mercato: IDOGEN is forecast to have no revenue next year.

Ricavi ad alta crescita: IDOGEN is forecast to have no revenue next year.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Insufficient data to determine if IDOGEN's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

Idogen Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Recent updates

Nasdaq Stockholm Decides to Delist the Shares of Idogen from Nasdaq First North Growth Market

Idogen AB (publ) to Report First Half, 2023 Results on Aug 23, 2023

Idogen AB (publ) Appoints Jan Holgersson to Its Board of Directors

High number of new and inexperienced directors

Idogen AB Announces Board Changes

Idogen AB (Publ) Announces First Patient Enters Idogen's Hemophilia Study Under the Ido 8 Program

Idogen AB (publ) Announces Board Changes

Idogen Receives Approval from the Regional Ethics Committee to Conduct Clinical Phase I/IIa Study

Idogen Appoints Christina Herder as Acting CEO

Redeye Updates Their Analysis of Idogen as Company Approaches Clinical Phase

Redeye Updates Their Analysis of Idogen as Company Approaches Clinical Phase

Idogen AB (Publ) Announces CEO Executive Changes

Idogen AB (publ) is Preparing to Start Clinical Phase 1/2A Study with IDO 8 in Norway

No independent directors

Idogen AB (publ) Announces Study Approval in Norway and Sweden

Idogen Strengthens the Organization Before the Clinical Development Phase

Idogen AB (Publ) Receives Approval from the Norwegian Medicines Agency, Noma, for the Start of Clinical Phase 1/2A Study with IDO 8

Idogen Receives Approval from the Swedish Medical Products Agency for the Clinical Phase I/IIa Study with IDO 8

Idogen AB (publ) has completed a Composite Units Offering in the amount of SEK 50.425465 million.

Idogen AB (Publ) Submits Application to Norwegian Medicines Agency to Begin Clinical Phase 1/2A Study of the Advanced Cell Therapy Treatment IDO 8 in Norway

Idogen Submits Clinical Trial Application

Idogen AB Submits an Application to the Swedish Medical Products Agency to Initiate A Clinical Phase 1/2A Study of the Cell Therapy Treatment IDO 8

Idogen AB (publ) Completes the Optimization of the GMP Manufacturing Process for the First Clinical Study with Its Tolerogenic Cell Therapy IDO 8

CEO & MD recently bought kr144k worth of stock

Idogen AB Receives Confirmation the European Patent Office Intends to Grant A Patent Application

New 90-day low: kr2.99

Idogen AB (publ) Announces Executive Changes

New 90-day low: kr3.08

New 90-day low: kr3.27

New 90-day low: kr3.63

New 90-day low: kr3.98

New 90-day low: kr5.06

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita